Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 673.50
Bid: 674.50
Ask: 675.00
Change: -2.00 (-0.30%)
Spread: 0.50 (0.074%)
Open: 676.00
High: 676.00
Low: 669.50
Prev. Close: 675.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

31 Mar 2010 07:00

null

Tate & Lyle PLC - 31 March 2010

STATEMENT ON ENTERING CLOSE PERIOD

In line with our usual practice, Tate & Lyle PLC issues the following update for the year ended 31 March 2010 ahead of the announcement of the full year results on 27 May 2010.

Underlying trading in the final quarter of the 2010 financial year has been consistent with our expectations outlined in the Interim Management Statement of 28 January 2010. However, currency movements, in particular the stronger US dollar, will benefit reported performance in the final quarter.1

Performance at our Ingredients businesses in the Americas and Europe during the final quarter of the 2010 financial year has been in line with expectations. Margins in our EU sugar operations have remained consistent with those achieved in the third quarter, and, as anticipated, Sucralose has continued to deliver volume growth at lower average selling prices.

We have continued to focus on strengthening the Group's balance sheet through operational efficiencies and optimising both working capital and capital expenditure. We expect underlying cash inflows in the quarter to offset the translation impact of the significantly stronger US dollar2, and therefore anticipate that reported net debt at 31 March 2010 will be broadly similar to the £864 million reported at 31 December 2009.

Footnotes

1 A 1 cent change in the sterling:US dollar exchange rate leads to a £1.3 million change in reported Profit before tax excluding exceptional items and amortisation of acquired intangible assets for the continuing operations (PBTEA) for the full year. As reported in the Interim Management Statement of 28 January 2010, we assumed a sterling:US dollar exchange rate of 1.68 in translating profits for the balance of the 2010 financial year.

2 Every 1 cent change in the sterling:US dollar exchange rate leads to a £6 million change in reported net debt. The closing sterling:US dollar exchange rate at 31 December 2009 was 1.62 and at 30 March 2010 was 1.51.

END

A conference call will be held today at 8.00am BST, hosted by Javed Ahmed, Chief Executive, and Tim Lodge, Group Finance Director. Participants are requested to dial in at least 5 minutes before the commencement of the call. Details are provided below:

Participant dial in number: +44 (0) 1452 555 566 (UK freephone 0800 694 0257)Conference ID: 66276891

A replay of this call will be available from two hours after the end of the live call, for 7 days until 6 April 2010.

Replay dial in number: +44 (0) 1452 55 00 00 (UK freephone 0800 953 1533)Replay passcode: 66276891#

For more information contact Tate & Lyle PLC:

Chris McLeish, Director of Investor RelationsTel: +44 (0) 20 7977 6211 or Mobile: +44 (0) 7919 102 730

William Baldwin-Charles, Head of Media RelationsTel: +44 (0) 20 7977 6165 or Mobile: +44 (0) 7810 151 425

About Tate & Lyle:

Tate & Lyle is a world-leading renewable food and industrial ingredients company, serving a global market from more than 45 production facilities throughout the Americas, Europe and South East Asia. Our efficient, large-scale manufacturing plants turn agricultural products, corn and cane sugar, into valuable ingredients for our customers. These ingredients add taste, texture, nutrition and increased functionality to products that millions of people around the world use or consume every day.

Tate & Lyle's range of leading branded food ingredients includes SPLENDA® Sucralose, PROMITOR™ Dietary Fiber, STA-LITE® Polydextrose, Tate & Lyle Fairtrade Sugar and Lyle's Golden Syrup. Tate & Lyle also produces branded industrial ingredients including Bio-PDO™, Ethylex® and Sta-Lok® paper starches; and staple ingredients such as high fructose corn syrup, sugar, ethanol, citric acid and basic starches. In addition to providing a wide range of ingredients our expert sales and product applications teams support customers by providing technical advice and proprietary consumer insight studies.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2009, Tate & Lyle employed 5,718 people in its subsidiaries and joint ventures, and sales totalled £3.55 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC

Copyright Business Wire 2010

Date   Source Headline
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.